2020

The Phoenix MICRON® IV system and OCT help evaluate promising compounds for treatment of age-related macular degeneration

Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using

2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON®, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

2020

Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity

In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON® IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by

2020

Imaging unanesthetized mice with the Phoenix MICRON® OCT provides consistent retinal degeneration measurements

In the recently published review, “Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss,” researchers from The Jackson Laboratory in Bar Harbor, Maine and Mahidol University in Bangkok, Thailand performed an extensive literature search to find mouse models of single-gene mutations leading to photoreceptor loss and retinal degeneration. Using the Phoenix MICRON® III and

2019

Treating retinitis pigmentosa with cassia seed: Retinal layer analysis with the Phoenix MICRON OCT and Insight software

Retinitis pigmentosa is a genetic disorder that leads to severe vision impairment and blindness. The photoreceptors die off in a self-propelling cycle of rod and cone dysfunction, leading to glial activation and death, leading to more dysfunction. There are a few experimental treatments but no widespread effective treatment or cure. Cassia seed is used in

2019

Phoenix MICRON® OCT tracks individual stem cells in the rat retina

In the July edition of Nanomedicine journal, Chemla et al demonstrate a fascinating and novel way to label and track individual photoreceptor precursor cells migrating within the retina with fluorescence and gold nanoparticle tagging using the Phoenix MICRON® and OCT. Many retinal diseases such as age-related macular degeneration and retinitis pigmentosa are characterized by photoreceptor

1 2 3 4 5